Structure Therapeutics Inc. Payments to Acquire Short-term Investments
Structure Therapeutics Inc. (GPCR) reported Payments to Acquire Short-term Investments of $692.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-06
- Structure Therapeutics Inc. payments to acquire short-term investments for the quarter ending 2026-06-30 was $44.63M, a 49.75% decline year-over-year.
- Structure Therapeutics Inc. payments to acquire short-term investments for the quarter ending 2026-03-31 was $647.47M, a 457.65% increase year-over-year.
- Structure Therapeutics Inc. payments to acquire short-term investments for the quarter ending 2025-12-31 was $93.62M, a 29.21% decline year-over-year.
- Structure Therapeutics Inc. payments to acquire short-term investments for the quarter ending 2025-09-30 was $248.82M, a 2.33% decline year-over-year.
- Structure Therapeutics Inc. payments to acquire short-term investments for fiscal 2025 was $547.38M, a 22.08% decline from fiscal 2024.
- Structure Therapeutics Inc. payments to acquire short-term investments for fiscal 2024 was $702.52M, a 68.33% increase from fiscal 2023.
- Structure Therapeutics Inc. payments to acquire short-term investments for fiscal 2023 was $417.36M, a 238.07% increase from fiscal 2022.
- Structure Therapeutics Inc. payments to acquire short-term investments for fiscal 2022 was $123.45M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $44.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $692.10M 10-Q · filed 2026-08-06 | $785.72M derived: sum of 3 quarters · filed 2026-08-06 | $1.03B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $647.47M 10-Q · filed 2026-05-07 | $741.09M derived: sum of 2 quarters · filed 2026-05-07 | $989.91M derived: sum of 3 quarters · filed 2026-05-07 | $1.08B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $93.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $342.45M derived: sum of 2 quarters · filed 2026-02-26 | $431.27M derived: sum of 3 quarters · filed 2026-08-06 | $547.38M 10-K · filed 2026-02-26 |
| 2025-09-30 | $248.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $337.65M derived: sum of 2 quarters · filed 2026-08-06 | $453.76M 10-Q · filed 2025-11-06 | $586.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $88.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $204.93M 10-Q · filed 2026-08-06 | $337.18M derived: sum of 3 quarters · filed 2026-08-06 | $591.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $116.11M 10-Q · filed 2026-05-07 | $248.36M derived: sum of 2 quarters · filed 2026-05-07 | $503.12M derived: sum of 3 quarters · filed 2026-05-07 | $786.71M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $132.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $387.01M derived: sum of 2 quarters · filed 2026-02-26 | $670.60M derived: sum of 3 quarters · filed 2026-02-26 | $702.52M 10-K · filed 2026-02-26 |
| 2024-09-30 | $254.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $538.35M derived: sum of 2 quarters · filed 2025-11-06 | $570.27M 10-Q · filed 2025-11-06 | $806.86M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $283.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $315.51M 10-Q · filed 2025-08-06 | $552.10M derived: sum of 3 quarters · filed 2026-02-26 | $567.03M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $31.92M 10-Q · filed 2025-05-08 | $268.51M derived: sum of 2 quarters · filed 2026-02-26 | $283.44M derived: sum of 3 quarters · filed 2026-02-26 | $259.18M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $236.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $251.52M derived: sum of 2 quarters · filed 2026-02-26 | $227.26M derived: sum of 3 quarters · filed 2026-02-26 | $417.36M 10-K · filed 2026-02-26 |
| 2023-09-30 | $14.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$9.33M derived: sum of 2 quarters · filed 2024-11-13 | $180.77M 10-Q · filed 2024-11-13 | $189.96M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$24.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $165.84M 10-Q · filed 2024-08-08 | $175.02M derived: sum of 3 quarters · filed 2024-08-08 | $221.01M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $190.10M 10-Q · filed 2024-05-09 | $199.28M derived: sum of 2 quarters · filed 2024-05-09 | $245.27M derived: sum of 3 quarters · filed 2024-05-09 | $271.90M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $9.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $55.17M derived: sum of 2 quarters · filed 2024-03-08 | $81.80M derived: sum of 3 quarters · filed 2024-03-08 | $123.45M 10-K · filed 2024-03-08 |
| 2022-09-30 | $45.98M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-17 | $72.61M derived: sum of 2 quarters · filed 2023-11-17 | $114.27M 10-Q · filed 2023-11-17 | |
| 2022-06-30 | $26.63M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-11-17 | $68.28M 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | $41.65M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |